Exploring the molecular mechanism of Licorice rose beverage anti-melasma based on network pharmacology, molecular docking technology and in vivo and in vitro experimental verification
Abstract Melasma is a pigmentation disease with refractory and high recurrence risk. Therefore, finding effective treatment has become the focus of research. The aim of this study was to reveal the mechanism of Licorice rose beverage (LRB) in treating melasma from the perspective of network pharmacology and in vitro and in vivo experimental techniques. Network pharmacological studies have shown that Isolicoflavonol, quercetin, kaempferol are the main active components of anti-melasma and TYR is the main target. Molecular docking studies have shown that these compounds have a good affinity for these targets. In vitro tyrosinase inhibition experiments showed that LRB could significantly inhibit tyrosinase activity. In vivo studies showed that LRB could significantly improve skin damage and skin pigmentation, reduce the activities of serum and skin tyrosinase in model mice, increase the activity of SOD in serum, and reduce the content of MDA in mice, showing a good effect of anti-melasma. In conclusion, these findings reveal the molecular mechanism of LRB in treating melasma and provided the scientific basis for this product's development and clinical application..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
ResearchSquare.com - (2024) vom: 24. März Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhai, Dan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| doi: |
10.21203/rs.3.rs-2900251/v1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XRA039599027 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XRA039599027 | ||
| 003 | DE-627 | ||
| 005 | 20240325130657.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230521s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21203/rs.3.rs-2900251/v1 |2 doi | |
| 035 | |a (DE-627)XRA039599027 | ||
| 035 | |a (ResearchSquare)10.21203/rs.3.rs-2900251/v1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhai, Dan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Exploring the molecular mechanism of Licorice rose beverage anti-melasma based on network pharmacology, molecular docking technology and in vivo and in vitro experimental verification |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Melasma is a pigmentation disease with refractory and high recurrence risk. Therefore, finding effective treatment has become the focus of research. The aim of this study was to reveal the mechanism of Licorice rose beverage (LRB) in treating melasma from the perspective of network pharmacology and in vitro and in vivo experimental techniques. Network pharmacological studies have shown that Isolicoflavonol, quercetin, kaempferol are the main active components of anti-melasma and TYR is the main target. Molecular docking studies have shown that these compounds have a good affinity for these targets. In vitro tyrosinase inhibition experiments showed that LRB could significantly inhibit tyrosinase activity. In vivo studies showed that LRB could significantly improve skin damage and skin pigmentation, reduce the activities of serum and skin tyrosinase in model mice, increase the activity of SOD in serum, and reduce the content of MDA in mice, showing a good effect of anti-melasma. In conclusion, these findings reveal the molecular mechanism of LRB in treating melasma and provided the scientific basis for this product's development and clinical application. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Hu, Yi |4 aut | |
| 700 | 1 | |a Liu, Li |4 aut | |
| 700 | 1 | |a Wang, Zhuxian |4 aut | |
| 700 | 1 | |a Liang, Peiyi |4 aut | |
| 700 | 1 | |a Jiang, CuiPing |4 aut | |
| 700 | 1 | |a Li, Hui |4 aut | |
| 700 | 1 | |a Zeng, Quanfu |4 aut | |
| 700 | 1 | |a Chen, Hongkai |4 aut | |
| 700 | 1 | |a Wu, Yufan |4 aut | |
| 700 | 1 | |a Guo, Yinglin |4 aut | |
| 700 | 1 | |a Yi, Yankui |4 aut | |
| 700 | 1 | |a Shen, Chunyan |4 aut | |
| 700 | 1 | |a Zhu, Hongxia |4 aut | |
| 700 | 1 | |a Liu, Qiang |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ResearchSquare.com |g (2024) vom: 24. März |
| 773 | 1 | 8 | |g year:2024 |g day:24 |g month:03 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.heliyon.2023.e22421 |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21203/rs.3.rs-2900251/v1 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XRA | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 24 |c 03 | ||